Cargando…

Resistance to immune checkpoint inhibitors in advanced lung cancer: Clinical characteristics, potential prognostic factors and next strategy

BACKGROUND: Immune checkpoint inhibitors (ICIs) have shown unprecedented clinical benefit in cancer immunotherapy and are rapidly transforming the practice of advanced lung cancer. However, resistance routinely develops in patients treated with ICIs. We conducted this retrospective study to provide...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Jiebai, Lu, Xinyuan, Zhu, Haixing, Ding, Ning, Zhang, Yong, Xu, Xiaobo, Gao, Lei, Zhou, Jian, Song, Yuanlin, Hu, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910216/ https://www.ncbi.nlm.nih.gov/pubmed/36776868 http://dx.doi.org/10.3389/fimmu.2023.1089026

Ejemplares similares

Impact of chronic obstructive pulmonary disease on immune checkpoint inhibitor efficacy in advanced lung cancer and the potential prognostic factors
por: Zhou, Jiebai, et al.
Publicado: (2021)

Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer
por: Chao, Yencheng, et al.
Publicado: (2022)

Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma
por: Chen, Yue, et al.
Publicado: (2022)

Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer
por: Zou, Xue-lin, et al.
Publicado: (2021)

Advances in immune checkpoint inhibitors induced-cardiotoxicity
por: Li, Xiang, et al.
Publicado: (2023)

Prognostic model of immune checkpoint inhibitors combined with anti-angiogenic agents in unresectable hepatocellular carcinoma
por: Li, Xiaomi, et al.
Publicado: (2022)

The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer
por: Ren, Sijia, et al.
Publicado: (2021)

Clinical outcomes of patients with HER2-mutant advanced lung cancer: chemotherapies versus HER2-directed therapies
por: Zhou, Jiebai, et al.
Publicado: (2020)

Prognostic nutritional index as a prognostic biomarker for gastrointestinal cancer patients treated with immune checkpoint inhibitors
por: Zhang, Lilong, et al.
Publicado: (2023)

Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors
por: Hou, Aohan, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management
por: Zhang, Qin, et al.
Publicado: (2021)

Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis
por: Lin, Xinqing, et al.
Publicado: (2022)

Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma
por: Xie, Fucun, et al.
Publicado: (2022)

Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy
por: Plesca, Ioana, et al.
Publicado: (2020)

Case report: Brain metastasis necrosis with immune checkpoint inhibitors plus chemotherapy for advanced non-small cell lung cancer
por: Niu, Lishui, et al.
Publicado: (2022)

Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma
por: Khair, Duaa O., et al.
Publicado: (2019)

Analysis of Tumor Glycosylation Characteristics and Implications for Immune Checkpoint Inhibitor’s Efficacy for Breast Cancer
por: Lv, Wenchang, et al.
Publicado: (2022)

Analysis of Tumor Microenvironment Characteristics in Bladder Cancer: Implications for Immune Checkpoint Inhibitor Therapy
por: Chen, Xingyu, et al.
Publicado: (2021)

A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer
por: Yan, Yi-Dan, et al.
Publicado: (2021)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Advances in CT features and radiomics of checkpoint inhibitor-related pneumonitis: A short review
por: Huang, Jie, et al.
Publicado: (2023)

Expanding the applications of immune checkpoint inhibitors in advanced lung cancer beyond disease progression
por: Chen, Chao, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management
por: Tang, Liansha, et al.
Publicado: (2021)

Acquired Resistance to Immune Checkpoint Blockades: The Underlying Mechanisms and Potential Strategies
por: Zhou, Binghan, et al.
Publicado: (2021)

Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
por: Chen, Siteng, et al.
Publicado: (2020)

Interaction between gut microbiota and immune checkpoint inhibitor-related colitis
por: Zhou, Guanzhou, et al.
Publicado: (2022)

Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment
por: Song, Yuxiao, et al.
Publicado: (2020)

Immune checkpoint inhibitor-associated toxicity in advanced non-small cell lung cancer: An updated understanding of risk factors
por: Hu, Xiangxiao, et al.
Publicado: (2023)

Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy
por: Kurago, Zoya, et al.
Publicado: (2023)

Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer
por: Zhou, Lin, et al.
Publicado: (2021)

TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer
por: Ge, Zhouhong, et al.
Publicado: (2021)

Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy
por: Wu, Jianmin, et al.
Publicado: (2021)

Different Expression Characteristics of LAG3 and PD-1 in Sepsis and Their Synergistic Effect on T Cell Exhaustion: A New Strategy for Immune Checkpoint Blockade
por: Niu, Bailin, et al.
Publicado: (2019)

Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
por: Zhang, Zhibo, et al.
Publicado: (2020)

Case Report: Persistent response to combination therapy of pemigatinib, chemotherapy, and immune checkpoint inhibitor in a patient with advanced intrahepatic cholangiocarcinoma
por: Zhang, Zhuochao, et al.
Publicado: (2023)

Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance
por: Zhou, Xiaoting, et al.
Publicado: (2022)

Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC
por: Signorelli, Diego, et al.
Publicado: (2022)

Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer
por: Zhou, Kexun, et al.
Publicado: (2023)

Bibliometric analysis of rheumatic immune related adverse events associated with immune checkpoint inhibitors
por: Zeng, Li, et al.
Publicado: (2023)

Diversity of Dominant Peripheral T Cell Receptor Clone and Soluble Immune Checkpoint Proteins Associated With Clinical Outcomes Following Immune Checkpoint Inhibitor Treatment in Advanced Cancers
por: Li, Ye, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_eefhmblmu7tdjpu5h19foq21h9